Siemens Healthcare introduces two new cloud-based solutions
Siemens Healthcare has introduced two new cloud-based solutions to optimize image management and radiology workflow.
The solutions will be hosted from the Siemens Healthcare Cloud Computing Center (HCCC), in Malvern, Pennsylvania, US.
In a strategic alliance with Dell, Siemens will deliver a cloud-based vendor-agnostic Image Sharing & Archiving (ISA) solution.
According to the company, the cloud-based vendor-neutral archive can help customers manage expanding image archives and achieve sustainable growth.
ISA provides the scalability to dynamically change in accordance with a facility's needs, and peace of mind with an efficient disaster recovery strategy.
Dell Healthcare and Life Sciences vice president and general manager James Coffin said the companies bring years of cloud computing experience to help customers solve their data management and archiving challenges.
Related Insight
Suppliers Directory
ENNOV - Medical Device and Drug Development Compliance Specialists
ENNOV INC. (Ennov) provides Ennov5 "Business Suite Solutions" to enable companies to obtain and maintain regulatory compliance while focusing their attention on the business of maximizing profitability by leveraging computing technology.
Automation > IT & Software > Suppliers
Cresset - Molecular Field Technology
Cresset develops and sells an innovative range of chemistry tools for molecular modellers, medicinal chemists and safety, in-licensing and IP specialists within the life science industry.
Automation > IT & Software > Suppliers
Exco InTouch - Mobile Internet Solutions for Patient Communication
Exco InTouch is the leading provider of global, secure, and regulatory compliant short messaging services and mobile internet solutions for patient communication to the Biopharmaceutical and Healthcare sectors.
Automation > IT & Software > Suppliers
Metris - Animal Behaviour Analysis Solutions
Metris B.V. is a trendsetter in the field of animal behaviour research. The company consistently develops and introduces innovative technologies for preclinical research, by automating behavioural research, ultrasonic vocalisation analysis and sleep research. Metris products are internationally marketed and supported by experienced staff of sales and service engineers.
Automation > IT & Software > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
IT & Software Intelligence
Biotechnology Solution Brief
Published by Brainloop
Automation > IT & Software > White Papers
Understanding Pasteurisation and Sterilisation Processes
Published by Tecnosoft
Automation > IT & Software > White Papers
Beyond Markush – Protecting Activity not Chemical Structure
Published by Cresset
Automation > IT & Software > White Papers
Accuri Revolutionizes Flow Cytometry
Published by Accuri Cytometers
Automation > IT & Software > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.